CellFE, Inc., a San Carlos, Calif.-based startup developing a microfluidics based device to deliver gene-editing molecules, raised $3.6m in an initial seed funding.

The round was co-led by Cota Capital and Dynamk Capital, and joined by Embark Ventures.

The funding is expected to close with additional investors by the end of January 2020.

Led by Alla Zamarayeva, CEO, CellFE focuses on the application of microfluidics in the process of delivering gene-editing molecules into human cells.

The company has developed technology that uses rapid cell compressions to drive cells to uptake molecules from the surrounding fluid. | To read full story, visit https://startuparound.com/read/1579194023.1732547/CellFE-Raises-$3.6M-in-Seed-Funding?ref=audio_experience